Price
No data yet.
Social Signal Score
Revenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Mark Lappe
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 110
- Beta
- 3.67
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 0.19
Financials
Revenue
$0.00-100.0%Net Income
$-36.65MEBITDA
$-30.48MFree Cash Flow
$-29.89MEPS (diluted)
$-2.34Shares Outstanding (diluted)
15.67M-13.7%Operating Expenses
$32.15MCash & Debt
$133.34MReturn of Capital
$0.00Revenue by Segment (annual)
$1.30MDividend per Share
$0.85Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.30M | $-140.06M | $-9.04 |
| 2024 | $200.0K | $1.69B | $116.58 |
| 2023 | $1.80M | $-241.36M | $-5.12 |
| 2022 | $2.19M | $-145.23M | $-3.62 |
| 2021 | $7.13M | $-81.77M | $-2.15 |
| 2020 | $12.81M | $-76.12M | $0.00 |
| 2019 | $9.09M | $-51.40M | $-1.41 |
| 2018 | $8.60M | $-31.16M | $-1.15 |
| 2017 | $8.39M | $-19.44M | $-0.68 |
| 2016 | $6.67M | $-8.27M | $-0.23 |
Valuation
INBXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
107+6.67%Social Signal Score
Mentions (2)
- Newsseekingalpha.com·1d ago·Neutral
Inhibrx: Market's Lukewarm Response To Yesterday's HNSCC Data Hard To Fathom Inhibrx (INBX) advances ozekibart and INBRX-106, targeting rare cancers and large immuno-oncology markets, with an FDA BLA decision for ozekibart due by April 2027. Ozekibart delivered a 52% risk reduction in chondrosarcoma progression and strong response rates in colorectal and Ewing sarcoma cohorts, fueling prior share price surges. INBRX-106, combined with Keytruda, showed a 48.3% cORR in head and neck cancer in data…
View source ↗ - Newsprnewswire.com·5d ago·Neutral
Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study – Event to be webcast live on Tuesday, September 8 th at 5:00 a.m. PT – SAN DIEGO, Sept.
View source ↗
Earnings
Fri, Nov 13(in 2 months)
Consensus estimate $-2.45 per share
Typical surprise -2.6% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-2.34 vs $-2.28miss
- Thu, May 14$-2.15 vs $-2.37beat
- Thu, Mar 19$-2.11 vs $-2.08miss
- Fri, Nov 14$-2.28 vs $-2.08miss
- Wed, Aug 13$-1.85 vs $-2.92beat
- Wed, May 14$-2.80 vs $-2.55miss
Estimates and results for INBX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by INBX officers and directors.
- Bought
- $13.4m
- Sold
- $21.6m
30 trades
4 trades
- Kayyem Jon Faizbought
- Forsyth Douglasbought
- Lappe Markbought
- Lappe Markbought
- Lappe Markbought
- Lappe Markbought
- Lappe Markbought
- Lappe Markbought
66 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in INBX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.